Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06332092 · ClinicalTrials.gov registry record · Phase 2
FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
A Phase 2 study of Head and Neck Squamous Cell Carcinoma, sponsored by Fulgent Pharma.
- Active
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 6
- Study locations
NCT06332092 is a Phase 2 study of Head and Neck Squamous Cell Carcinoma that is active but no longer recruiting, run by Fulgent Pharma. The registered enrollment target is 46 participants, below the 117-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (61% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT06332092, a Phase 2 study of Head and Neck Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Fulgent Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this FID-007 Clinical Trial is to compare the efficacy of different dosing regimens of FID-007 in combination with Cetuximab in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC). The main questions it aims to answer are: to evaluate the efficacy, and to characterize the safety and tolerability. Eligible participants will be enrolled and randomized to 1 of 2 arms of FID-007 with fixed-dose Cetuximab in each 28-day cycle.
Conditions Studied
Interventions
- DRUG FID007
Study Locations (6)
Texas
- Texas Oncology - Baylor Charles A. Sammons Cancer Center - Dallas
- Texas Oncology - Northeast Texas Cancer & Research Institute - Tyler
Arkansas
- Highlands Oncology - North Hills - Fayetteville
California
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
Florida
- Moffitt Cancer Center Magnolia Campus - Tampa
Indiana
- Fort Wayne Medical Oncology and Hematology - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2024-04-10 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06332092
The ClinicalTrials.gov registry entry for NCT06332092 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 117-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (61% lower). The listed sponsor is Fulgent Pharma, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which FID007 is the first listed.
NCT06332092 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Texas, Arkansas, California.
Frequently Asked Questions
What is clinical trial NCT06332092 about?
NCT06332092 is a clinical study titled "FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma". The goal of this FID-007 Clinical Trial is to compare the efficacy of different dosing regimens of FID-007 in combination with Cetuximab in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC). The main questions it aims to answer are: to evaluate the efficacy, and to ...
What is the current status of trial NCT06332092?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2024-04-10. Estimated completion is 2026-12-31.
What conditions does trial NCT06332092 study?
This clinical trial studies the following conditions: Head and Neck Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06332092?
The interventions under investigation include: FID007 (DRUG).
Who is sponsoring clinical trial NCT06332092?
This trial is sponsored by Fulgent Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06332092 being conducted?
This trial has 6 study locations across Arkansas, California, Florida, Indiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.